Abstract
In 2003, the Market for Monoclonal Antibodies in the treatment of Cancer is just short of $2.8 billion and growing at a phenomenal rate. The market is fueled by leading products such as Rituxan and Herceptin; however, other products continue to demand more attention each year. This study reviews market data for the years 2001 to the present and forecasts the market to 2008, including Kaloramafs estimates of the competitive market share in 2008 based on the current pipeline and likely market conditions. Although the primary markets considered in the study are the United States and Europe, estimates of other significant international regions are included.
Products in research and development play a vital part in the continued growth of this market. There are approximately six serious products in Phase III development and another six in Phase II. Other areas of focus for this study include demographics and statistics for cancer, corporate profiles for leading and emerging companies, and product pipeline by development stage. With more than 10 million new cancer cases each year and approximately 50 percent of these in the growing 55 and over population, innovative treatments in cancer will continue to grow at phenomenal rates.
This study represents the second volume in a series of reports on advanced cancer therapeutics. The first volume, The Emerging Cancer Vaccines Market, was published in February 2004; the next will cover other immunomodulators and is due out in June 2004.
View Cart
